OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The right ventricle tamed	1169
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	882
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	741
Chymase-1: a “MAST”-er switch in COPD?	359
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	229
Missing airways, ventilation defects and conductive airway physiology in asthma	221
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	199
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	181
A breath of the future: a novel human model for COPD and beyond	158
The lung that rules the heart	149
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	146
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	144
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	142
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	137
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	129
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	124
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	123
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	123
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	123
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	116
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	108
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	105
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	103
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	101
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	98

Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	94
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	93
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	93
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	91
Soteria: deliverance from harm?	91
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	89
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	88
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	86
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	84
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	81
Treatment algorithm for pulmonary arterial hypertension	80
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	80
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	80
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	80
The environmental impact of inhaled therapy: making informed treatment choices	79
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	79
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	78
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	78
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	78
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	76
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	74
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	72
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	71
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	69
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	67
Childhood asthma: pathogenesis and phenotypes	66
Prognostic phenotypes of early-stage lung adenocarcinoma	65
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	65
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	64
The limits of normal of pulmonary arterial wedge pressure	64
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	63
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	63
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	63
Pleural mesothelioma: surgery questioned again?	62
List ofEuropean Respiratory Journalpeer reviewers 2023	60
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	60